To the Editor We read with interest the recent phase 3 clinical trial data1 and Barbieri’s accompanying Editorial2 on the use of clascoterone, a novel topical antiandrogen, in treating moderate to severe facial acne. In the Editorial,2 Barbieri highlights the need to identify specific subgroups or acne phenotypes for which topical antiandrogens may be most effective. Of critical consideration, and not discussed in either the clinical trial1 or Editorial,2 topical antiandrogens may be particularly helpful for managing acne in individuals receiving masculinizing hormone therapy (MHT).
Marks DH, Mansh MD. Potential Role for Topical Antiandrogens in the Management of Acne Among Patients Receiving Masculinizing Hormone Therapy. JAMA Dermatol. 2020;156(12):1380–1381. doi:10.1001/jamadermatol.2020.4380
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.